Industry news that matters to you.  Learn more

NextGen Sciences Launches Multiple Protein Plasma Biomarker Assay for Multiple Sclerosis

Reading time: 1 – 2 minutes

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched the first phase of its multiple protein (multiplex) assays in plasma, for CNS diseases. The plasmamultiplesclerosis15 assay simultaneously measures 15 human plasma proteins that are thought to have potential as biomarkers in multiple sclerosis disease. The launch of plasmamultiplesclerosis15 is part of NextGen Sciences strategy of becoming a leading player in the growing central nervous system (CNS) and oncology biomarker markets.

NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to continue to add candidate biomarker proteins to the plasmamultiplesclerosis15 assay, through its own R&D efforts and through collaborations and partnerships.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of plasmamultiplesclerosis15 demonstrates that we are very focused on the protein content of our assays to address the needs of our clients across different therapeutic areas. We continue to deliver on our plans to develop multiplex protein assays that will help to establish the company as a market leader in protein biomarker discovery and qualification.

Source: NextGen Sciences